Barclays Reiterates CHF 80 Price Target for Novartis (NOVN)

Barclays set a CHF 80 target price on Novartis (VTX:NOVN) in a research report sent to investors on Tuesday. The firm currently has a sell rating on the stock.

A number of other equities research analysts also recently weighed in on the company. Baader Bank set a CHF 95 target price on Novartis and gave the stock a buy rating in a research report on Friday, February 16th. Kepler Capital Markets set a CHF 88 price objective on Novartis and gave the company a buy rating in a research report on Friday, February 9th. Berenberg Bank set a CHF 91 price objective on Novartis and gave the company a neutral rating in a research report on Friday, January 26th. Morgan Stanley set a CHF 92 price objective on Novartis and gave the company a buy rating in a research report on Thursday, January 25th. Finally, S&P Global set a CHF 91 price objective on Novartis and gave the company a neutral rating in a research report on Thursday, January 25th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of CHF 88.50.

Shares of Novartis (VTX NOVN) opened at CHF 79.98 on Tuesday. The firm has a market capitalization of $209,920.00 and a P/E ratio of 25.97. Novartis has a 52-week low of CHF 72.45 and a 52-week high of CHF 88.30.

WARNING: “Barclays Reiterates CHF 80 Price Target for Novartis (NOVN)” was originally published by BBNS and is the sole property of of BBNS. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://baseballnewssource.com/markets/barclays-reiterates-chf-80-price-target-for-novartis-novn/1906301.html.

Novartis Company Profile

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped


Leave a Reply

 
© 2006-2018 BBNS.